Sanofi reported robust sales growth in Q1 2026, with Sarclisa sales rising 30.1% to $193.21 million and Dupixent sales increasing 30.8% to $4.85 billion. The company is expanding Sarclisa's reach with an on-body injector to compete in the multiple myeloma market. Additionally, the Pharma Launches segment grew 49.6% to $1.38 billion, highlighting Sanofi's strong pipeline and fundamentals that make it an attractive investment opportunity.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
